Dr.
Giordano is a co-founder and President and CEO of TheraVasc.
He has held senior management positions at six separate
biotechnology companies, including Message, Nucleonics and
Alteris, where he has been involved in business planning,
licensing, directing research and development efforts,
fundraising and financial management. He is a
consultant/advisor to three venture funds, a consultant to the
Biomedical Research Foundation, and was recently appointed by
the Governor of Louisiana to the Innovation Council. Dr
Giordano has secured over $6M in federal funding for the
Companies he has managed and has 11 issued and a number of
pending patent applications. Before beginning his career in
biotech, Dr. Giordano was a senior scientist at Abbott
Laboratories.
Dr. Kevil is a co-founder of TheraVasc and is currently working with the Company part-time as its Chief Scientific Officer, providing expertise in vascular physiology and pathology. His research is focused on the relationship between inflammation and vascular growth and function, and his seminal work has revealed detailed mechanistic relationships between angiogenesis and inflammation, making him an internationally recognized expert in inflammatory vascular pathology. Dr. Kevil currently serves on the editorial boards of several prestigious journals, inlculding Cardiovascular Research, American Journal of Physiology, Free Radical Biology and Medicine, Inflammatory Bowel Diseases, and the Open Pathlogy Journal. Dr. Kevil has received several research awards and honors.